No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2210
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin ; volume:11 ; number:1 ; day:1 ; month:8 ; year:2011 ; pages:1 ; date:12.2011
BMC pharmacology ; 11, Heft 1 (1.8.2011), 1, 12.2011
- Urheber
-
Frey, Reiner
Mück, Wolfgang
Unger, Sigrun
Reber, Michael
Krätzschmar, Jörn
Becker, Corina
Wensing, Georg
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1471-2210-11-S1-P25
- URN
-
urn:nbn:de:101:1-2019073119000635328966
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Frey, Reiner
- Mück, Wolfgang
- Unger, Sigrun
- Reber, Michael
- Krätzschmar, Jörn
- Becker, Corina
- Wensing, Georg
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat
Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
Vicriviroc Is a Novel, Potent CCR5 Inhibitor With Outstanding Pharmaceutic, Pharmacokinetic and PharmaCodynamic (PK/PD) Properties
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study
Pharmacokinetic/pharmacodynamic evaluation of gamithromycin against rabbit pasteurellosis
Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis
Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat
Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
Vicriviroc Is a Novel, Potent CCR5 Inhibitor With Outstanding Pharmaceutic, Pharmacokinetic and PharmaCodynamic (PK/PD) Properties
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study
Pharmacokinetic/pharmacodynamic evaluation of gamithromycin against rabbit pasteurellosis
Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis
Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat
Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
Vicriviroc Is a Novel, Potent CCR5 Inhibitor With Outstanding Pharmaceutic, Pharmacokinetic and PharmaCodynamic (PK/PD) Properties
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study
Pharmacokinetic/pharmacodynamic evaluation of gamithromycin against rabbit pasteurellosis
Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial